Insider Buying: Avid Bioservices Inc (CDMO) Director Acquires 50,000 Shares of Stock
Avid Bioservices Inc (NASDAQ:CDMO) Director Mark R. Bamforth bought 50,000 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were acquired at an average cost of $2.25 per share, with a total value of $112,500.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Shares of Avid Bioservices Inc (NASDAQ:CDMO) opened at $2.49 on Thursday. The stock has a market capitalization of $114.49, a price-to-earnings ratio of -3.07 and a beta of 2.23. Avid Bioservices Inc has a one year low of $2.24 and a one year high of $5.78.
Avid Bioservices (NASDAQ:CDMO) last posted its earnings results on Monday, December 11th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.15). Avid Bioservices had a negative return on equity of 52.55% and a negative net margin of 39.23%. The business had revenue of $12.78 million for the quarter, compared to analyst estimates of $13.54 million. research analysts anticipate that Avid Bioservices Inc will post -0.57 earnings per share for the current fiscal year.
WARNING: This piece was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://theolympiareport.com/2018/02/22/insider-buying-avid-bioservices-inc-cdmo-director-acquires-50000-shares-of-stock.html.
About Avid Bioservices
Avid Bioservices, Inc, formerly Peregrine Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. The Company delivers pharmaceutical products through its contract manufacturing business and through licensing its development-stage immunotherapy products.
Receive News & Ratings for Avid Bioservices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avid Bioservices and related companies with MarketBeat.com's FREE daily email newsletter.